Postpartum Low-Dose Aspirin and Preeclampsia
{ "Postpartum Low-Dose Aspirin and Preeclampsia Study", "This study is looking at whether taking low-dose aspirin (81mg) after delivery can help improve blood vessel health in women who had severe preeclampsia. Preeclampsia is a serious condition during pregnancy that causes high blood pressure and can affect organs. The study will enroll about 100 women who had severe preeclampsia before delivery. You would be randomly assigned to take either low-dose aspirin or a placebo (an inactive pill) daily for up to three weeks after delivery. The main goal is to see if aspirin improves how well your blood vessels expand, which is measured by something called flow-mediated dilation (FMD). The study status is currently unclear.", "design": "This is an interventional study that plans to enroll about 100 women. Participants will be randomly assigned to receive either low-dose aspirin or a placebo.", "commitments": "You would take either low-dose aspirin (81mg) or a placebo oral capsule daily for up to 3 weeks post-delivery. Your blood vessel function (Flow-Mediated Dilation) will be measured up to 3 weeks postpartum.", "compensation": "Not stated in the trial record.", "follow_up": "Your blood vessel function will be measured up to 3 weeks postpartum.", }
- Study design
- Not specified.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Not specified.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Postpartum Low-Dose Aspirin and Preeclampsia
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Aleha Aziz, MD, MPH · PRINCIPAL_INVESTIGATOR · Columbia University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Change in Flow-Mediated Dilation (FMD)Up to 3 weeks postpartum
This is designed to measure if patients with preeclampsia with severe features diagnosed antepartum or intrapartum, will experience an increase in Flow-Mediated Dilation (FMD) - a measure of endothelial function - within 3 weeks after delivery when taking daily LDA in the postpartum period.